Opportunities in China
At China Focus@BIO Philadelphia, we are going to bring together 100+ Chinese executives from pharma, medical device companies and investment institutions. Some attendees are seeking assets and strategic partners in following categories：
- Indication: Cancer, kidney disease, autoimmune disease
- Product type: mAB, protein, peptide, small molecule drugs in phase II or later.
Contact us if you are interested in exploring potential possibilities in China market.
|More Opportunities Available|
Participating Chinese Companies Spotlight
Brii Biosciences is dedicated to serving patients’ needs and improving public health in China. Our mission is to help Chinese patients gain earlier access to more affordable, innovative medicines through partnerships, best-in-class research and development, and the disruptive application of digital and data insight.
Delos Capital is a private equity fund that partners with strong management teams and strategic owners to invest in lower middle market companies.
Shenzhen Share Capital is the venture capital investment team focusing on new drug development, biotechnology, medical device, and medical health.
Northern Light Venture Capital is China-focused venture capital firm targeting early stage opportunities of innovation and disruptive technology.
|Register to Schedule 1-1 Meeting with Other Attendees|
- June 2, Philadelphia (Online Application Deadline: May 22)
- Partnering opportunities with potential Chinese investors.
- Exhibition booth for your company at China Focus@BIO Philadelphia with a surprise discount.
- Media coverage and promotion on our English and Chinese platforms.
- Opportunity for a 5-day sponsored business development trip in China to meet 100+ investors and corporate executives.
|Submit Application Now|
Click here to learn more about preliminary schedule and featured prizes.